Press Releases
Leveraging CLD technology to overcome associated challenges
High-titer biologics production with maximized productivity and quality is crucial for efficient biomanufacturing. In this article for the Innovations in Pharmaceutical Technology magazine, Yingji Jin, a Lead Scientist in our Cell Line Development Group, discusses how Samsung Biologics' CLD platform with high-titer capabilities can help streamline biologics manufacturing to deliver essential treatments to patients faster.
Read more
High-titer biologics production with maximized productivity and quality is crucial for efficient biomanufacturing. In this article for the Innovations in Pharmaceutical Technology magazine, Yingji Jin, a Lead Scientist in our Cell Line Development Group, discusses how Samsung Biologics' CLD platform with high-titer capabilities can help streamline biologics manufacturing to deliver essential treatments to patients faster.
Read more